VINC

Vincerx Pharma, Inc. (NASDAQ:VINC) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Palo Alto, California. The company went public in May 2020 and focuses on researching and developing novel cancer therapies to address unmet medical needs. Vincerx operates in the highly specialized field of oncology drug development, with a particular emphasis on targeting specific cellular mechanisms involved in cancer progression. The company is currently in the clinical and preclinical stages of development, with no approved products generating revenue yet.